ライフサイエンスコーパス: IVGTT

1 IVGTT-derived insulin sensitivity was reduced by (means

2 ient and research volunteer records for 3806 IVGTT glucose and insulin profiles.

3 For an effective evaluation of AIRg, IVGTT glucose loading should be adjusted for glucose dis

4 Glucose disposal during an IVGTT depends on a complex interaction of both insulin-d

5 tion (rate of glucose uptake [Rd]) during an IVGTT is more similar to the dynamics of the interstitia

6 perfectly normal glucose disposal during an IVGTT with no differences when compared with nondiabetic

7 ng not-fasting glycemia and by performing an IVGTT on days 15 and 30 post-Tx.

8 ynamic responses of glucose or insulin to an IVGTT is an important risk factor for type 2 diabetes.

9 improvements in beta-cell function using an IVGTT were similar between SG and RYGB.

10 in disposition index (DI), measured with an IVGTT, over 5 years was three times higher in case patie

11 Cardiovascular Health Study (N = 2,631) and IVGTT-derived measures in participants from the HERITAGE

12 An OGTT and IVGTT were repeated during the 12th week of treatment.

13 etes during the trial returned for OGTTs and IVGTTs 8 months after study medications were stopped.

14 ed data from a total of 280 paired OGTTs and IVGTTs during a median follow-up of 46 months.

15 here would be an optimum anthropometry-based IVGTT load calculation that, by achieving a trend-free D

16 demonstrating that a body surface area-based IVGTT load calculation could provide for a more generall

17 ghest diastolic blood pressures and the best IVGTT insulin responses during baseline testing.

18 t reduction in the total insulin area during IVGTTs, which was highly significant (P < 0.001), and wi

19 ractional glucose disappearance rates during IVGTTs (P = 0.28).

20 f blood glucose values) were calculated from IVGTT results.

21 initial values of S(I) and S(G) derived from IVGTT's performed at study entry, there was a 10- to 20-

22 After baseline oral (OGTT) and intravenous (IVGTT) glucose tolerance testing, subjects were assigned

23 could provide for a more generally invariant IVGTT DeltaG0.

24 SI, calculated by minimal model analysis of IVGTT results, changed by only 4 +/- 14% during 12 weeks

25 d decreased GSIS in the first few minutes of IVGTT.

26 on in AIRg, DeltaG0 and gVOL with a range of IVGTT loads, both observed and simulated, we explored th

27 Two sets of IVGTTs were performed.

28 d intravenous glucose tolerance tests (OGTT; IVGTT), hyperinsulinemic-euglycemic clamps, and measurem

29 are not analogous to those from the clamp or IVGTT.

30 phase insulin release from either the HGC or IVGTT.

31 For the paired IVGTT based on 33% extraction, the area under the insuli

32 al insulin levels were matched in the paired IVGTTs by adjusting the portal insulin dose in proportio

33 ors of postpartum IGT were a low first-phase IVGTT insulin response (P = 0.0001), a diagnosis of GDM

34 Intravenous glucose tolerance test IVGTT and OGTT insulin secretion rate (ISR) and sensitiv

35 EHC), by intravenous glucose tolerance test (IVGTT) and by oral glucose tolerance test (OGTT) in 3 di

36 olism by intravenous glucose tolerance test (IVGTT) and euglycemic-hyperinsulinemic clamp.

37 from an intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp (HGC) in 17 nondiabetic s

38 The intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulin

39 rough an intravenous glucose tolerance test (IVGTT) and serum biochemistry was analyzed before the in

40 ars, the Intravenous glucose tolerance test (IVGTT) has been used extensively in researching the path

41 An intravenous glucose tolerance test (IVGTT) in the control group (n=24) and the Cudt group (n

42 s of the intravenous glucose tolerance test (IVGTT) to document progression of resistance.

43 es to an intravenous glucose tolerance test (IVGTT) to identify novel protein contributors to glucose

44 ) and an intravenous glucose tolerance test (IVGTT) were performed between the 24th and 28th week of

45 in-vivo Intravenous Glucose Tolerance Test (IVGTT).

46 (I.V.) glucose (I.V. glucose tolerance test [IVGTT]), arginine and glucose-potentiated arginine (gluc

47 +) underwent i.v. glucose tolerance testing (IVGTT) between the years 1964-82.

48 during intravenous glucose tolerance tests (IVGTT) remains critical for stringent evaluation of nove

49 Intravenous glucose tolerance tests (IVGTTs) for assessment of insulin sensitivity and beta-c

50 mulated intravenous glucose tolerance tests (IVGTTs) in anesthetized dogs to test the following hypot

51 Ts) and intravenous glucose tolerance tests (IVGTTs) were performed at 15-month intervals for up to 5

52 Intravenous glucose tolerance tests (IVGTTs) were performed at baseline and 3 months later to

53 odified intravenous glucose tolerance tests (IVGTTs) were performed in dogs in which insulin was admi

54 during intravenous glucose tolerance tests (IVGTTs).

55 on [via intravenous-glucose-tolerance tests (IVGTTs)].Fifty-four participants completed the study [35

56 on was restored in type 2 diabetic after the IVGTT (Phi1 x 10: 104 +/- 54 vs 228 +/- 88; P < 0.05, pr

57 physiology of diabetes mellitus and AIRg-the IVGTT-induced acute insulin response to the rapid rise i

58 Consequently, the IVGTT glucose load needed for an invariant DeltaG0 was p

59 using the acute insulin response during the IVGTT (AIRG).

60 was correlated with S(i) estimated from the IVGTT and the HGC (r = 0.59 and 0.76, respectively; P <

61 icularly within the first few minutes of the IVGTT, with a significantly lower area under the excursi

62 In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats

63 For these latter three IVGTTs, the exogenous glucose bolus was labeled with 3-[

64 Acute insulin response to IVGTT (AIR(GLU) ) and GPAIS (AIR(max) ) were the most ac

65 s of oral and intravenous glucose tolerance (IVGTT), body composition, and fat distribution.

66 lin (SI) levels, and i.v. glucose tolerance (IVGTTs).

67 in women with the largest reduction in total IVGTT insulin area after 1 year of treatment.